TrialSignal transduction and targeted therapy2025

First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study.

Guoming Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.